Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape

Access Activity

Overview / Abstract:

Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now.


Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Ranathunga et al, 2020). Although survival has improved in recent years due to considerable advances in treatment, the rate of relapse remains high (ASCO, 2021; Samra et al, 2020). One reason for this is that older patients are often unable to tolerate curative therapy, leading to a lack of effective therapeutic options andless-than-optimal outcomes (Aldoss et al, 2019). In addition, variables such as comorbidities and cytogenic disease features make the selection of appropriate treatment difficult. Therefore, it is essential that the multidisciplinary team have a comprehensive understanding of emerging efficacy and safety data regarding novel therapeutic strategies. In this activity, Amir Fathi, MD, will update clinicians on strategies for developing individualized management plans in order to maximize treatment tolerability and improve outcomes for their patients with ALL.


Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.


Upon completion of this activity, participants should be able to
Discuss predictive and prognostic markers that can individualize treatment selection for patients with B-cell ALL
Assess emerging efficacy and safety data on novel therapeutic strategies for B-cell ALL
Evaluate strategies to optimize the safety and tolerability of novel therapies for B-cell ALL


Feb 14, 2023


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 CME | 1.0 NCPD | 1.0 CPE | MOC | ILNA



Presenters / Authors / Faculty

Amir Fathi, MD
Associate Professor of Medicine
Harvard Medical School

Activity Specialities / Related Topics

Pharmacology, Oncology / Cancer / Radiation Therapy, Hematology

Sponsors / Supporters / Grant Providers

This activity is supported by independent educational grants from BeiGene, Bristol Myers Squibb, Merck, and Seagen.

Keywords / Search Terms

i3 Health i3 Health i3 Health i3 health, ALL, acute lymphoblastic lymphoma, lymphoma, B-Cell lymphoma, CNE, free CNE, free CE CME, free CE CME, free CE CME, NCPD, free NCPD, online NCPD, online NCPD, CME ,Free CE CME, Free CE CME, ANCC Free CE CME Free CE CME Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map